selpercatinib

Overview

Selpercatinib (LOXO-292) is a highly selective RET kinase inhibitor approved for RET-altered thyroid cancers and non-small cell lung cancer. It demonstrates durable responses in patients with activating RET mutations or fusions.

Evidence in the corpus

• Activating RET mutations in metastatic medullary thyroid carcinoma patients (PN7, PN8) identified by WGTA (POG program) guided selpercatinib (LOXO-292) selection; PN7 achieved 1423 days stable disease on selpercatinib PMID:24326773

Resistance mechanisms

Cancer types (linked)

• MTNN

Sources

This page was processed by crosslinker on 2026-05-09.